Patents Assigned to Agomab Therapeutics
  • Anti-MET agonist antibody for use in the treatment of colorectal cancer
    Patent number: 11834507
    Abstract: The present invention relates to treatment of cancer using agonist anti-MET antibodies or fragments thereof. In particular, the invention relates to treatment of colorectal cancer using agonist anti-MET antibodies or fragments, typically colorectal cancer associated with chronic inflammation and/or gene mutations in the colon and in the gastrointestinal tract in general. The invention further relates to treating intestinal fibrosis using agonist anti-MET antibodies.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: December 5, 2023
    Assignee: Agomab Therapeutics
    Inventor: Paolo Michieli
  • Anti-MET antibodies and uses thereof
    Patent number: 11098126
    Abstract: The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: August 24, 2021
    Assignee: AGOMAB THERAPEUTICS BVBA
    Inventor: Paolo Michieli